deoxyepinephrine has been researched along with Kidney Failure, Chronic in 11 studies
Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patients were randomly divided into two groups: 96 took ibopamine at a dosage of 100 mg/day (group A) and 93 served as controls (group B)." | 2.68 | Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial. ( Bazzato, G; Bignamini, AA; Bonomini, M; Bonomini, V; Brancaccio, D; Cappelli, P; Cossu, M; De Biase, V; Docci, D; Fanciulli, E; Feletti, C; Fracasso, A; Galmozzi, C; La Manna, G; Locatelli, F; Marai, P; Mioli, V; Mosconi, G; Oldrizzi, L; Piccoli, G; Roccatello, D; Scarpioni, L; Sorba, GB; Stefoni, S; Sverzellati, E, 1996) |
| "Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months)." | 2.65 | Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug. ( Colí, L; Docci, D; Mosconi, G; Prandini, R; Stefoni, S; Vangelista, A, 1982) |
| " Furthermore, ibopamine-quinidine pharmacokinetic interaction and the effects of food on plasma kinetics were evaluated in NS." | 1.27 | Clinical pharmacokinetics of ibopamine on different diseases and conditions. ( Lodola, E; Ventresca, GP, 1988) |
| " Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients." | 1.27 | Pharmacokinetics of ibopamine in patients with renal impairment. ( Bovio, G; Longo, A; Pataccini, R; Pocchiari, F; Salvadeo, A; Ventresca, GP; Villa, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stefoni, S | 4 |
| Docci, D | 3 |
| Vangelista, A | 1 |
| Mosconi, G | 4 |
| Colí, L | 2 |
| Prandini, R | 3 |
| Nicaise, J | 1 |
| Vryens, R | 1 |
| Ghirardi, P | 1 |
| Bauer, R | 1 |
| Brusoni, B | 1 |
| La Manna, G | 1 |
| Bonomini, V | 1 |
| Mioli, V | 1 |
| Fanciulli, E | 1 |
| Feletti, C | 1 |
| Cappelli, P | 1 |
| Bonomini, M | 2 |
| Locatelli, F | 1 |
| Marai, P | 1 |
| Bazzato, G | 1 |
| Fracasso, A | 1 |
| Brancaccio, D | 1 |
| Galmozzi, C | 1 |
| Scarpioni, L | 1 |
| Sverzellati, E | 1 |
| Sorba, GB | 1 |
| Cossu, M | 1 |
| Piccoli, G | 1 |
| Roccatello, D | 1 |
| Oldrizzi, L | 1 |
| De Biase, V | 1 |
| Bignamini, AA | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Smit, AJ | 1 |
| Nanni-Costa, A | 1 |
| Scolari, MP | 1 |
| Liviano-D'Arcangelo, G | 1 |
| Cianciolo, G | 1 |
| Ventresca, GP | 2 |
| Lodola, E | 1 |
| Tarján, J | 1 |
| Salvadeo, A | 1 |
| Villa, G | 1 |
| Bovio, G | 1 |
| Pocchiari, F | 1 |
| Pataccini, R | 1 |
| Longo, A | 1 |
| Pistocchi, E | 1 |
| Turci, F | 1 |
| Baldrati, L | 1 |
2 reviews available for deoxyepinephrine and Kidney Failure, Chronic
| Article | Year |
|---|---|
The use of ibopamine in chronic renal failure: long-term results.
Topics: Deoxyepinephrine; Diuretics; Humans; Kidney Failure, Chronic; Time Factors | 1990 |
Dopamine agonists for oral use.
Topics: Administration, Oral; Deoxyepinephrine; Dopamine Agents; Female; Heart Diseases; Humans; Kidney Fail | 1988 |
2 trials available for deoxyepinephrine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Creatinine; Deoxyepine | 1982 |
Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial.
Topics: Adolescent; Aged; Creatinine; Deoxyepinephrine; Disease Progression; Dopamine Agonists; Female; Huma | 1996 |
7 other studies available for deoxyepinephrine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Ibopamine in geriatric patients with cardiac and chronic renal failure: a clinical study.
Topics: Aged; Deoxyepinephrine; Diuretics; Dopamine; Female; Heart Diseases; Humans; Kidney Failure, Chronic | 1982 |
Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.
Topics: Adult; Aged; Body Weight; Creatinine; Deoxyepinephrine; Dopamine; Female; Glomerular Filtration Rate | 1981 |
[Effects of an orally administered dopamine derivative on renal excretion].
Topics: Administration, Oral; Deoxyepinephrine; Dopamine; Humans; Kidney Failure, Chronic | 1980 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Topics: Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Chemical | 1988 |
Pharmacokinetics of ibopamine in patients with renal impairment.
Topics: Adolescent; Adult; Aged; Deoxyepinephrine; Dopamine; Female; Half-Life; Humans; Kidney Failure, Chro | 1988 |
Effect of ibopamine on the progression of chronic renal failure.
Topics: Adult; Creatinine; Deoxyepinephrine; Diuretics; Dopamine; Female; Glomerulonephritis; Humans; Kidney | 1986 |